Abstract
Introduction
SS, described by Henrik Sjö gren in 1933, is a chronic inflammatory disorder characterized by lymphocytic infiltration of epithelial tissue in exocrine glands and extraglandular sites [1] . Lacrimal and salivary gland infiltration 25 results in the classic sicca syndrome of dry eyes and dry mouth in >90% of patients [2] . However, SS is a heterogeneous disease; extraglandular infiltration can threaten organ function and carries an excess mortality, mainly due to lymphoproliferative disease, which occurs in up 30 to 10% of patients [3] . It may occur alone (primary SSpSS) or in association with other autoimmune diseases (e.g. SLE).
pSS has been called an autoimmune epithelialitis [4] , an apt term since the lymphocytic infiltrate is centred on epi- 35 thelial cells in each organ that it affects. This includes glandular epithelial cells in the lacrimal and salivary glands, tubular epithelial cells in the kidney, respiratory epithelia and submucosal glands within the lung and biliary epithelia in hepatobiliary disease [5] . 40 It classically occurs in middle-aged women, but can occur in other groups [6] . It has been estimated to affect 0.050.23% of the adult population [7] . It may be asymptomatic with the incidental discovery of autoantibodies [8] or it may present with the sicca complex, consti- 45 tutional symptoms or other organ involvement [9] .
Renal disease in pSS
Renal involvement in pSS was first described in the 1960s with reports of the typical tubular defects [1012] . These included biopsy series that highlighted tubulointerstitial 50 inflammation as the most common renal lesion [13] . Renal involvement in pSS is the result of two distinct pathophysiological processes: epithelial disease with a predominantly mononuclear lymphocytic infiltration resulting in tubulointerstitial nephritis (TIN) (Fig. 1 ) and 55 non-epithelial disease with a secondary immune complexmediated process resulting in glomerulopathy.
Prevalence of renal disease in pSS
Three major series of renal involvement in pSS come from Spain and Greece [2, 7, 14] . These retrospective 60 studies looked for overt disease and identified renal involvement in 5%, 4.9% and 4.3% of patients, respectively.
Ramos-Casals et al. [2] defined renal involvement as one of proteinuria >0.5 g/day, active urinary sediment, Goules et al. [14] defined renal involvement as one of low specific gravity (<1.010) after water deprivation, urinary pH >7 for >6 months, renal colic with nephrolithiasis or nephrocalcinosis, Fanconi syndrome, impaired excre-tory function, proteinuria, active urine sediment or histological GN or TIN. When retrospectively applied to a cohort of 715 patients, 35 had evidence of renal disease. A recent UK retrospective study of 152 pSS patients found that 10 (6.5%) had renal involvement, defined by 10 the presence of renal tubular acidosis or GN [15] .
However, in prospective studies of randomly selected pSS patients, specifically looking for tubular defects, the prevalence of renal involvement is much higher. The most recent studies estimate proximal injury to be present in 15 1042%, dRTA in 524% and a concentrating defect in 1728% [1619] ( Table 1) .
Prevalence of different renal lesions
Two large series with biopsy data confirm earlier reports that TIN is the predominant lesion, found in 75% of pa-20 tients, with the remaining 25% of patients having glomerular disease [20, 21] .
Maripuri et al.
[21] reviewed all renal biopsies from a cohort of 7276 patients with pSS between 1967 and 2007. Twenty-four renal biopsies were identified, 25 17 (71%) of which had primarily TIN, while 7 (29%) had glomerulopathy. Of these, two had co-existent mild TIN.
Ren et al. [20] described a cohort of 130 pSS patients. Forty-one of these underwent biopsy, with 80% demon-30 strating TIN and 20% glomerular disease. However, the Goules et al. [14] cohort did not show the same predominance of TIN; of the 33 biopsied patients, 52% had GN, 35% had TIN and 12% had both [14] . [26, 27] and it has been suggested that specific therapies could be employed dependent on the predominant cell subtype found at the presenting biopsy [28] . Whether the histological severity or the predominant cell subtype correlate with patient outcome is 50 unclear. While infiltration at extraglandular sites often coincides with glandular epithelial infiltration, whether one can use salivary gland histology to assess the severity of renal disease is not known. IL-22, a cytokine produced by Th17 cells, has increased expression in salivary gland biopsies of pSS, and Th17 cells are the predominant source [31] . It was recently demonstrated that increased IL-17 in the salivary glands of pSS patients was from both CD4 + T cells and mast 70 cells. After treatment with rituximab (RTX), tissue expression of IL-17 decreased, but this was associated with a reduction in mast cell numbers rather than CD4 + T cells [32] . RTX appears to have more than just an antiB cell effect; similar modulation of the Th17 response by RTX 75 has been shown in the setting of RA [33].
Epithelial renal disease in pSS
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Evidence for an important role of B cells in pSS includes a high prevalence of autoantibodies, hypergammaglobulinaemia, increased risk of lymphoma, germinal centre with hypokalaemic symptoms, including paralysis [37] . Seven per cent of patients in one series presented with hypokalaemic paralysis and one patient had a cardiac arrest [20] . dRTA may also manifest as nephrolithiasis or nephrocalcinosis (Fig. 2) , causing renal colic or urosepsis.
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In prospective studies designed to look for dRTA in pSS, it is relatively common, in between 5% and 23% of patients [16, 18, 19] ; its presence is associated with antiRo and La antibodies, longer disease duration, xerostomia, hypertension, higher creatinine and proteinuria.
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Hypergammaglobulinaemia is also associated with dRTA in pSS [19] . In cohorts of known renal pSS, dRTA is even more common; as high as 70% in one series [20] .
We have previously shown that vacuolar H + -ATPase and anion exchanger 1, transporters crucial to 35 a-intercalated cell function, are undetectable on immunohistochemistry in pSS dRTA [38] . Autoantibodies to these proteins have been demonstrated in patients with pSS dRTA [39] , but not consistently [40] . Congenital carbonic anhydrase II (CA II) deficiency also results in dRTA. 40 Autoantibodies to CA II are associated with pSS, especially dRTA. Mice immunized with CA II develop a sialadenitis similar to pSS and a proportion of these mice had TIN [41] . Takemoto et al.
[42] screened 46 patients with pSS, 13 of whom had dRTA. Compared with controls, 45 autoantibodies to CA II were increased in the pSS cohort and highest in those with dRTA. The same group subsequently immunized mice with CA II. CA II antibodies were associated with the development of a mild TIN in 50% and dRTA on ammonium chloride testing [43] . 50 Supportive management of dRTA includes supplementation of bicarbonate and potassium (e.g. oral potassium citrate) and close nephro-urological follow-up to prevent complications from nephrolithiasis.
Nephrogenic diabetes insipidus
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The initial reports of tubular dysfunction in pSS were of nephrogenic diabetes insipidus (NDI) [10, 11] ; it is caused by dysfunction of the principal cells of the collecting duct. Copyedited by: SCR MANUSCRIPT CATEGORY: REVIEW Presentation is with polydipsia, polyuria and nocturia. It may only be apparent on specific testing with the water deprivation test. It is as prevalent in the general pSS population as dRTA, being present in 1728% of patients ( Table   5 1). In biopsy-proven TIN it is present in 75% of patients, with only a quarter of these patients being symptomatic [14] . pSS is a disease of adulthood, and the thirst mechanism is almost always robust enough to maintain the serum sodium within the normal range [44] , thus specific therapies for NDI (e.g. NSAIDs, diuretics) are not warranted. The full Fanconi syndrome is rare in pSS TIN (3% [20] ), but evidence of PTC dysfunction is much more common.
Proximal tubular dysfunction
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The most sensitive marker, tubular proteinuria (e.g. retinol binding protein), is present in 1042% in the general pSS series and up to 87% of those with known renal disease ( Table 1) .
Other acquired tubular defects
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There are case reports of pSS affecting other tubular segments, causing acquired Bartter or Gitelman-like syndromes [4549] . Intriguingly, one of these cases was reported to have an autoantibody to the NaCl co-transporter (NCC) [48] , the transporter affected by Gitelman syndrome. 
Non-epithelial renal disease in pSS
Histopathology of pSS GN
The majority of glomerular disease reported in pSS is immune complexmediated, usually the characteristic were cryoglobulinaemic in the Goules et al. series [14] .
Cryoglobulins are the result of B cell expansion causing the synthesis of IgM, which binds antigen and IgG. These immune complexes bind to endothelial cells, activate complement and recruit inflammatory cells, causing 10 small vessel vasculitis. In the kidney this manifests as MPGN, either alone or as part of a systemic vasculitis.
GN in pSS occurs later in the disease course than TIN. It is also associated with lymphoma development and thus increased morbidity and mortality [14, 50] .
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Glomerulopathy presents with typical glomerular features including haematuria, proteinuria, hypertension, reduced glomerular filtration rate and nephrotic syndrome ( Table  2 ). There are various patterns of GN involvement described in SS (supplementary Table S1 , available at 20 Rheumatology Online).
Decreased excretory function
Decreased excretory function is present in a relatively small proportion of those with renal involvement in pSS, being present in 2731% in the larger series [14, 20] 25 (supplementary Table S2 , available at Rheumatology Online). It can occur in those with either interstitial or glomerular disease. In the Goules et al. cohort, 54% of those with TIN had reduced excretory function compared with 12% in those with glomerular disease. It was 30 suggested that this may reflect the clinically silent and therefore possibly untreated nature of interstitial disease. If present, renal impairment in pSS TIN tends to be mild to moderate. However, progressive renal disease can 35 occur, and rates as high as 12% of patients with renal pSS requiring dialysis have been reported [14] .
Screening
Given the multiple renal lesions that can occur with pSS and the relative difficulty in recognizing them, we have 40 compiled a guideline for physicians treating pSS patients to help screen for pSS-associated disease and refer the patient to nephrology services if appropriate (supplementary data, guide to screening for renal involvement in pSS, available at Rheumatology Online). We have deliberately 45 avoided specialist renal investigations so that screening these patients is feasible in the general clinic setting. These guidelines represent our opinion only and are not based on empirical evidence. While HCQ or MTX is the mainstay of uncomplicated pSS, steroids, CYC, anti-proliferative agents, calcineurin inhibitors and biologic agents (e.g. RTX) have been used to manage resistant or extraglandular disease [56, 57] . In 60 addition to a lack of evidence for treatment of extraglandular pSS, there are no randomized studies on the management of pSS TIN, with treatment based on retrospective data of TIN treatment, again with conflicting results [58, 59] . 65 
TIN
In Maripuri et al.'s cohort [21], 88% were treated with steroids and 53% had additional immunosuppression. The majority had stable renal function; only 18% had progressive renal disease. Ren et al. [20] did not distinguish 70 between glomerular and interstitial disease when discussing treatment, but the majority of the cohort had interstitial disease and were treated with immunosuppression (largely steroids alone). The Greek group gave supportive treatment but not immunosuppression to those with inter-75 stitial disease [14] .
We treat acute TIN with MMF and a weaning course of steroids, reserving B celldepleting therapy for resistant disease. The clinical benefit of this strategy and how long it should be continued is the focus of current study.
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Treatment of glomerular disease is based on the histological lesion. Within the renal cohorts described there is no consistent treatment of any of the glomerular disease (supplementary Table S3 under way [63] . We can gain limited information on renal pSS from these trials, but it was interesting to note that five of six patients with renal involvement in recent registry data from France improved with RTX treatment [64] . Other biologic treatments may offer new avenues for the treat-
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ment of pSS TIN. pSS patients may have increased levels of B cell activating factor [65] , especially those with lymphoma. Belimumab, an antiB cell activating factor antibody, has been trialled successfully in phase 2 studies in pSS [66] , 40 improving symptom scores.
As Th17 cells appear to have an important role in epithelial inflammation in pSS, secukinumab, an anti-IL17 antibody, may have a role in the treatment of pSS, including renal SS. Furthermore, abatacept is another 45 potential therapy for renal pSS; a recent study showed that it improved salivary histology and saliva production in pSS [67] .
Conclusion
Renal pSS is an underdiagnosed problem that can pre-50 sent in a variety of different and covert ways. The pathogenesis of the pSS TIN lesion is likely to be the same as other epithelial lesions in pSS, and T cell responses appear to be important in this. Whether pSS TIN can provide insights into other forms of TIN (e.g. drug-related TIN) 55 or even acute transplant rejection remains to be seen. There is clearly much to be learned from this fascinating interaction of the immune system and the secretory epithelium.
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